Alcon, Inc. (ALC)
|Net Income (ttm)||457.00M|
|Ex-Dividend Date||May 3, 2022|
|Day's Range||56.96 - 59.23|
|52-Week Range||56.18 - 88.78|
|Price Target||83.19 (+43.0%)|
|Earnings Date||Aug 16, 2022|
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surg... [Read more...]
Financial PerformanceFinancial Statements
According to 14 analysts, the average rating for ALC stock is "Buy." The 12-month stock price forecast is 83.19, which is an increase of 42.99% from the latest price.
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
AERIE PHARMACEUTICALS - INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigat...
NEW ORLEANS , Sept. 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigat...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aerie Pharmaceutic...
Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.
Aerie set to be bought by Alcon for $770 million
New Jersey-based biotech firm Aerie is seeing its shares move higher amid news of it being bought by Aerie Pharmaceuticals.
NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or t...
Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday. The post Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie ...
Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.
GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, ...
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
GENEVA--(BUSINESS WIRE)--Alcon Reports Second Quarter 2022 Results
Does Alcon (ALC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ST. CATHARINES, Ontario--(BUSINESS WIRE)---- $ALC--Algoma Central Corporation (TSX: ALC) announced today that it has sold Station Mall, a large regional shopping complex located in Sault Ste. Marie, Ont...
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.
GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500.0 Million Senior Notes Offering
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
GENEVA--(BUSINESS WIRE)--Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.
GENEVA--(BUSINESS WIRE)--Alcon Reports First Quarter 2022 Results
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2022 Annual General Meeting
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.